Pan-EGFR inhibitor targeting EGFR 19del, L858R/T790M and C797S triple-mutations: Design, synthesis, and pharmacological evaluation
- 21 August 2025
- journal article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 164, 108878
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81872263)
This publication has 39 references indexed in Scilit:
- From challenges to solutions: A review of fourth-generation EGFR tyrosine kinase inhibitors to overcome the C797S triple mutation in non-small cell lung cancerEuropean Journal of Medicinal Chemistry, 2024
- Catalytic Lysine745 targeting strategy in fourth-generation EGFR tyrosine kinase inhibitors to address C797S mutation resistanceEuropean Journal of Medicinal Chemistry, 2024
- The combination therapy using tyrosine kinase receptors inhibitors and repurposed drugs to target patient-derived glioblastoma stem cellsBiomedicine & Pharmacotherapy, 2024
- The new N2, N4-diphenylpyridine-2,4-diamine deuterated derivatives as EGFR inhibitors to overcome C797S-mediated resistanceBioorganic Chemistry, 2024
- Cell-active, irreversible covalent inhibitors that selectively target the catalytic lysine of EGFR by using fluorosulfate-based SuFEx chemistryEuropean Journal of Medicinal Chemistry, 2023
- In-silico method for elucidation of prodigiosin as PARP-1 inhibitor a prime target of Triple-negative breast cancerBioorganic Chemistry, 2023
- P3.02b-119 YH25448, a Highly Selective 3rd Generation EGFR TKI, Exhibits Superior Survival over Osimertinib in Animal Model with Brain Metastases from NSCLCJournal of Thoracic Oncology, 2017
- Osimertinib: First Global ApprovalDrugs, 2016
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- GROMACS: Fast, flexible, and freeJournal of Computational Chemistry, 2005